Addex Therapeutics Shuts Down ADX71149 Epilepsy Program Following Phase II Study Results
Monday, 22 July 2024, 06:15
Addex Therapeutics Terminates its Epilepsy Program
Addex Therapeutics has officially announced the termination of its epilepsy program.
Phase II Study Results
In late April, the Phase II study for the product candidate ADX71149 (JNJ-40411813) did not achieve its set objectives.
Impact on Partnerships
The failure of this program could reshape the future collaboration with Janssen Pharmaceutica. Here are the key points:
- Termination of Epilepsy Program
- Phase II Study failed to meet objectives
- Implications for partnerships and future candidates
Conclusion
The decision taken by Addex Therapeutics to halt this program reflects the inherent risks in drug development, especially within the epilepsy treatment landscape.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.